Compass Pathways plc (CMPS) saw its shares jump sharply in U.S. premarket trading on Monday, building on gains from the prior week. Investors reacted positively to the company's announcement of an accelerated regulatory pathway for its lead drug candidate, COMP360, a synthetic psilocybin therapy for treatment-resistant depression. The stock traded at $12.39 as of 6:03 a.m. EDT, representing a 19.5% increase from Friday's close of $10.37. Regular trading on the Nasdaq is set to begin at 9:30 a.m. Eastern.
The company disclosed that the U.S. Food and Drug Administration (FDA) has allowed a rolling submission of its New Drug Application (NDA) for COMP360. This approach permits Compass to submit sections of the application as they are completed, rather than waiting for the entire package to be finalized. The move is seen as a significant step toward potentially bringing the treatment to market more quickly.
Management is scheduled to address investors during a fireside chat at the RBC Capital Markets Global Healthcare Conference in New York on Tuesday at 10:00 a.m. ET. A replay of the session will be available for 30 days, the company said.
COMP360 is a lab-made version of psilocybin, the active compound in magic mushrooms, and is being developed for patients with treatment-resistant depression who do not respond to conventional antidepressants. The drug has received FDA Breakthrough Therapy designation and is also part of the U.K. Innovative Licensing and Access Pathway.
CEO Kabir Nath emphasized the significance of the regulatory acceleration, describing COMP360 as a differentiated option for patients with limited alternatives. He stated that the company aims to complete a robust clinical package by the fourth quarter of 2026. Additionally, Compass announced that COMP360 has been granted a Commissioner's National Priority Voucher, which could shorten the FDA review period to just one or two months.
Compass also provided an update on its clinical timeline. The company expects to release 26-week data from its Phase 3 COMP006 trial early in the third quarter of 2026, and it reiterated its guidance for a final NDA submission in the fourth quarter of the same year.
On the financial front, Compass ended March with $466.0 million in cash and equivalents, a significant increase from $149.6 million at the end of December. The company stated that this cash position should fund operations into 2028. However, a closer look at the first-quarter results reveals an operating loss of $42.9 million. The company reported net income of $91.2 million, but this figure was boosted by a $130.9 million non-cash gain on warrant liabilities. Research and development spending decreased to $26.5 million from $30.9 million in the same quarter last year.
Following the update, analysts have adjusted their price targets. Maxim Group's Jason McCarthy raised his target to $20 from $12, maintaining a Buy rating, citing the priority voucher's potential to accelerate commercial timelines. Other analysts, including Morgan Stanley's Judah Frommer and RBC Capital's Leonid Timashev, have also recently raised their targets.
The competitive landscape for depression treatments remains intense. Johnson & Johnson's Spravato is currently the approved supervised-treatment standard for treatment-resistant depression. Meanwhile, other development-stage companies such as Atai Life Sciences, Beckley Psytech, and GH Research are advancing their own psychedelic-based therapies. Compass highlights that over 7,300 treatment centers are already equipped for multi-hour sessions, suggesting that COMP360 could be integrated into existing healthcare infrastructure.
Despite the positive momentum, Compass outlined several risks. The company cautioned that full Phase 3 safety data may differ from earlier results, and the rolling review or priority voucher may not ultimately lead to faster FDA approval. Commercialization, insurance coverage, and reimbursement also remain uncertain. For now, the stock's movement is driven more by regulatory timing than by clinical data, and the key question is whether management can convince investors this week that accelerating the filing process also makes a successful commercial launch feasible.
